Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Hepatitis D: Bulevirtide

Friday 17 September 2021

Our portfolio of liver diseases has grown again, this time to include hepatitis D. The new HDV entry inhibitor, bulevirtide (Hepcludex®) is now listed on our interactions checker. Bulevirtide is currently licensed in Europe and is expected to be approved by the FDA in 2022. 

Bulevirtide has been added to our Overview of Interactions tables. We have also uploaded a new PK Fact Sheet about bulevirtide.

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016